



WEST VIRGINIA DRUG UTILIZATION REVIEW (DUR) BOARD MEETING

February 15, 2023

Kepro Team

- **Chip Shook, PMP, CSM** – Executive Director of Pharmacy Management
- **Cory Chambliss** – Operations Director
- **Scott Donald, PharmD** – Director of Clinical Services
- **Alena Mitchell, PharmD** – Clinical Account Manager

Population-Based Interventions

- A. Diagnosis of COPD with concurrent benzodiazepine
- B. Multiple drugs with QT prolonging potential
- C. Co-administration of levothyroxine and gastrointestinal agents
- D. Psychiatric therapies in pregnancy with adverse fetal effects
- E. Suggestions?

Population-Based Interventions

Criteria	Medium to High Risk	Total
COPD + BZD	678	2264
QT prolonging drugs	910	3246
Levothyroxine + GI drugs	862	3654
Psychiatric drugs + pregnancy	165	948



INTERVENTION RANKING



QUESTIONS?
